Tyra Biosciences
  • Our Approach
  • Pipeline & Targets
  • Our People
  • Patients
  • For Investors
Select Page
Tyra Biosciences raises $106M in Series B financing to advance novel pipeline of therapies targeting acquired resistance in oncology

Tyra Biosciences raises $106M in Series B financing to advance novel pipeline of therapies targeting acquired resistance in oncology

by tyraadmin | Mar 31, 2021 | Fundraising

– Financing led by Nextech Invest with participation from Cormorant Asset Management, BVF Partners, L.P., Janus Henderson Investors, and Logos, along with existing investors Alta Partners, RA Capital, Boxer Capital of Tavistock Group, and Canaan – Hiroomi Tada, MD,...
Tyra Biosciences raises $50M to develop therapies targeting acquired resistance in oncology

Tyra Biosciences raises $50M to develop therapies targeting acquired resistance in oncology

by tyraadmin | Jan 10, 2020 | Fundraising

– Round co-led by Alta Partners, RA Capital, Boxer Capital of Tavistock Group, and Canaan, representing a group of seasoned early-stage and crossover investors – Experienced team well positioned to tackle acquired resistance, a devastating reality for patients...

Recent News

  • Tyra Biosciences raises $106M in Series B financing to advance novel pipeline of therapies targeting acquired resistance in oncology
  • Tyra Biosciences raises $50M to develop therapies targeting acquired resistance in oncology

Categories

  • Fundraising
  • Contact
  • Terms & Conditions
  • Privacy Policy
© Copyright 2025 Tyra Biosciences, Inc. Site Design